⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19507806 | 0.81 | — | — | |
| SCHEMBL23893927 | 0.77 | — | — | |
| SCHEMBL19869243 | 0.75 | — | — | |
| SCHEMBL19869244 | 0.75 | HTT (0.32) | — | |
| SCHEMBL22899768 | 0.75 | — | — | |
| SCHEMBL21646536 | 0.70 | HAVCR2 (0.31) | — | |
| SCHEMBL24526948 | 0.70 | ACHE (0.41) | — | |
| SCHEMBL22899683 | 0.70 | HTT (0.47) | — | |
| SCHEMBL21646790 | 0.70 | — | — | |
| SCHEMBL22015518 | 0.69 | HAVCR2 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023230002-A1 | NLRP3 INFLAMMASOME INHIBITORS | VenatoRx Pharmaceuticals, Inc. (US) | 2023-11-30 | — | — | WO | disclosed |
| US-20230059136-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-23 | — | — | US | disclosed |
| WO-2022115417-A1 | SULFONYL UREA NLRP3 INFLAMMASOME INHIBITORS | VenatoRx Pharmaceuticals, Inc. (US) | 2022-06-02 | — | — | WO | disclosed |
| US-20210332020-A1 | PHENYLSULFONYLUREA DERIVATIVES USEFUL AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2021-10-28 | — | — | US | disclosed |
| WO-2021188450-A1 | NLRP3 MODULATORS | ZOMAGEN BIOSCIENCES LTD (US) | 2021-09-23 | — | — | WO | disclosed |
| US-20210147349-A1 | PHENYLSULFONYLUREA DERIVATIVES USEFUL AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2021-05-20 | — | — | US | disclosed |
| WO-2021009566-A1 | N-((1,2,3,5,6,7-HEXAHYDRO-S-INDACEN-4-YL)CARBAMOYL)-4,5,6,7-TETRAHYDROBENZOFURAN -2-SULFONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS NLPR3 MODULATORS FOR THE TREATMENT OF MULTIPLE SCLEROSIS (MS) | ZOMAGEN BIOSCIENCES LTD (US) | 2021-01-21 | — | — | WO | disclosed |
| WO-2021009567-A1 | NLRP3 MODULATORS | ZOMAGEN BIOSCIENCES LTD (US) | 2021-01-21 | — | — | WO | disclosed |